Recovery signals are improving, but Protiviti’s regulatory exposure keeps near-term consolidated growth under pressure. [2][3]
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-07-23 |
| Length | 50 minutes |
| EPS | $0.26 |
| EPS consensus | $0.26 |
| Revenue | $1.3B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25
All RHI earnings · Back to RHI overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.